Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM

Posted by Francis Steltz on Sep 2nd, 2026

Legal & General Group Plc bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 33,072 shares of the company’s stock, valued at approximately $8,095,000. Legal & General Group Plc owned about 0.06% of Axsome Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of AXSM. GAMMA Investing LLC lifted its holdings in Axsome Therapeutics by 14.9% during the second quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock worth $85,000 after acquiring an additional 45 shares during the period. Birchview Capital LP boosted its position in Axsome Therapeutics by 1.0% in the fourth quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock worth $1,107,000 after purchasing an additional 61 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Axsome Therapeutics by 3.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock valued at $351,000 after purchasing an additional 65 shares during the period. Xponance LLC grew its stake in Axsome Therapeutics by 2.4% in the 4th quarter. Xponance LLC now owns 3,265 shares of the company’s stock valued at $596,000 after purchasing an additional 76 shares during the period. Finally, Assetmark Inc. increased its position in shares of Axsome Therapeutics by 7.2% during the 1st quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after purchasing an additional 79 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Insider Transactions at Axsome Therapeutics

In related news, Director Roger Jeffs sold 286 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total transaction of $70,407.48. Following the sale, the director directly owned 58,653 shares in the company, valued at approximately $14,439,195.54. This represents a 0.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Susan Mahony sold 300 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the transaction, the director directly owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. This trade represents a 20.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 183,229 shares of company stock valued at $42,666,176. 20.60% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Up 2.2%

Shares of NASDAQ AXSM opened at $202.83 on Wednesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The stock has a market capitalization of $10.62 billion, a PE ratio of -54.09 and a beta of 0.65. Axsome Therapeutics, Inc. has a one year low of $112.90 and a one year high of $260.19. The business’s fifty day moving average price is $225.66 and its 200-day moving average price is $207.10.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Zacks Research raised shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Truist Financial upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and issued a $290.00 target price on shares of Axsome Therapeutics in a research note on Monday. Finally, BMO Capital Markets assumed coverage on shares of Axsome Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $310.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.60.

Get Our Latest Stock Report on AXSM

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.